<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7385132\results\search\testTrace\results.xml">
  <result pre="by the World Health (1). Presentation of symptoms for COVID-19" exact="infection" post="can be seen 2â€&quot;14 days after exposure. These symptoms"/>
  <result pre="of acute lung injury and ARDS, ongoing clinical trials are" exact="testing" post="the hypothesis that blocking the complement cascade ameliorates disease"/>
  <result pre="age was the strongest predictor of a poor outcome with" exact="infection" post="(33, 35, 37). Male sex has also been proposed"/>
  <result pre="found in the endothelial cells of the kidney (57). Viral" exact="infection" post="could induce tubular damage through the deposition of the"/>
  <result pre="in two Afro-American patients with high-risk APOL1 genotype and COVID-19" exact="infection" post="showed a collapsing focal segmental glomerulosclerosis (62, 63). However,"/>
  <result pre="known to have a higher risk of upper respiratory tract" exact="infection" post="and pneumonia due to their persistent proinflammatory state with"/>
  <result pre="who had received antithymocyte globulin in the weeks before the" exact="infection" post="(66). Until more data is available, the rules to"/>
  <result pre="Until more data is available, the rules to prevent viral" exact="infection" post="in the general population apply to transplant patients (hand"/>
  <result pre="the general population apply to transplant patients (hand hygiene, sanitization," exact="social distancing," post="and avoiding areas where infected patients could be present)"/>
  <result pre="patients could be present) (73). Transplant patients with potential COVID-19" exact="infection" post="should not access the transplant center due to risk"/>
  <result pre="deceased donor transplants should continue. However, donors at risk of" exact="infection" post="should not be accepted since RNAemia was reported in"/>
  <result pre="for non-life-saving organs should be considered in order to prevent" exact="infection" post="of the recipient during the post-transplant period. Even then,"/>
  <result pre="for poor outcome during COVID-19 infection, the impact of the" exact="infection" post="on other kidney diseases, like end-stage renal disease, is"/>
  <result pre="of 7,154 hemodialyzed patients, about 2% were confirmed having COVID-19" exact="infection" post="and only about 50% of them presented fever while"/>
  <result pre="longer time to clear the virus requiring longer time in" exact="isolation" post="corresponding with the outbreak of SARS in 2003 (79,"/>
  <result pre="for Disease Control and Prevention (CDC) (84). Early recognition and" exact="isolation" post="of individuals with respiratory infection, isolation of infected patients"/>
  <result pre="(84). Early recognition and isolation of individuals with respiratory infection," exact="isolation" post="of infected patients from other hemodialyzed patients, and the"/>
  <result pre="for communication whenever possible (86). COVID-19 Treatment Currently, no specific" exact="treatment" post="against SARS-CoV-2 has been developed, but research thus far"/>
  <result pre="data from an ongoing RCT showed decreased inflammatory markers in" exact="treatment" post="group Siltuximab Anti-IL-6 chimeric monoclonal Ab Decrease inflammatory markers"/>
  <result pre="Antivirals Lopinavir/Ritonavir Lopinavir/Ritonavir is a protease inhibitor approved for the" exact="treatment" post="of HIV (108). Lopinavir was approved for the treatment"/>
  <result pre="the treatment of HIV (108). Lopinavir was approved for the" exact="treatment" post="of SARS-CoV during the epidemic of 2003 because it"/>
  <result pre="results, a Chinese clinical trial (ChiC-TR2000029308) in patients with SARS-CoV-2" exact="infection" post="showed that treatment with lopinavirâ€&quot;ritonavir added to standard supportive"/>
  <result pre="clinical trial (ChiC-TR2000029308) in patients with SARS-CoV-2 infection showed that" exact="treatment" post="with lopinavirâ€&quot;ritonavir added to standard supportive care was not"/>
  <result pre="62 COVID-19 positive patients (not peer-reviewed) patients treated with hydroxychloroquine" exact="treatment" post="showed an improvement in the clinical recovery and in"/>
  <result pre="would be prudent. Favipiravir Favipiravir is a drug approved for" exact="treatment" post="of severe influenza virus infection in China. It is"/>
  <result pre="is a drug approved for treatment of severe influenza virus" exact="infection" post="in China. It is a new type of RNA-dependent"/>
  <result pre="viral RNA (108, 112). It is currently being tested for" exact="treatment" post="of Ebola virus infection and, in the future, might"/>
  <result pre="It is currently being tested for treatment of Ebola virus" exact="infection" post="and, in the future, might be useful to treat"/>
  <result pre="The use of convalescent plasma was recommended as an empirical" exact="treatment" post="during outbreaks of Ebola virus in 2014 and as"/>
  <result pre="of Ebola virus in 2014 and as a protocol for" exact="treatment" post="of MERS (118). Shen et al. (118) administered convalescent"/>
  <result pre="10 matched control patients (92). Several other ongoing trials are" exact="testing" post="the safety/efficacy profile of convalescent plasma transfusion in patients"/>
  <result pre="are exploring the effectiveness and safety of glucocorticoids in the" exact="treatment" post="of COVID-19. JAK-STAT Inhibitors JAK-STAT inhibitors, like baricitinib, fedratinib,"/>
  <result pre="pre-proof clinical trial that demonstrated the efficacy of the MSC" exact="treatment" post="in patients with ARDS secondary to Influenza A (H7N9)"/>
  <result pre="treatment in patients with ARDS secondary to Influenza A (H7N9)" exact="infection" post="(124). Several ongoing clinical trials are testing the mesenchymal"/>
  <result pre="Influenza A (H7N9) infection (124). Several ongoing clinical trials are" exact="testing" post="the mesenchymal stem cells therapy against SARS-CoV-2. IL-6-Inhibitors Tocilizumab,"/>
  <result pre="with anti-inflammatory effects approved in China and Japan for the" exact="treatment" post="of acute pancreatitis and sepsis (123). There is an"/>
  <result pre="(123). There is an ongoing clinical trial (NCT04393311) that is" exact="testing" post="the safety and efficacy of ulinastatin compared to placebo"/>
  <result pre="Anakinra Anakinra has been approved by the FDA for the" exact="treatment" post="of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease. It"/>
  <result pre="those that received high-dose of Anakinra in combination with standard" exact="treatment" post="had a faster respiratory improvement compared to 16 patients"/>
  <result pre="raised concern for the use of these drugs during the" exact="infection" post="(8). However, the increased expression of ACE2 could limit"/>
  <result pre="ARBs reduce Ang II-mediated lung damage and therefore attenuate COVID-19" exact="infection" post="(127). In a retrospective study of 6,272 patients with"/>
  <result pre="calcium-channel blockers, beta-blockers or thiazide diuretics and the risk of" exact="infection" post="or of having a severe disease in 5,894 patients."/>
  <result pre="inhibitor. Cell. (2020) 181:271â€&quot;80.e8. 10.1016/j.cell.2020.02.05232142651 14.LiXGengMPengYMengLLuS. Molecular immune pathogenesis and" exact="diagnosis" post="of COVID-19. J Pharm Anal. (2020) 10:102â€&quot;8. 10.1016/j.jpha.2020.03.00132282863 15.ShiYWangYShaoCHuangJGanJHuangXet"/>
  <result pre="220:1â€&quot;13. 10.1016/j.trsl.2020.04.00732299776 22.SmeethLThomasSLHallAJHubbardRFarringtonPVallancePRisk of myocardial infarction and stroke after acute" exact="infection" post="or vaccination. N Engl J Med. (2004) 351:2611â€&quot;8. 10.1056/NEJMoa04174715602021"/>
  <result pre="(S-OIV) infection. AJR Am J Roentgenol. (2009) 193:1488â€&quot;93. 10.2214/AJR.09.359919933638 27.TangNBaiHChenXGongJLiDSunZAnticoagulant" exact="treatment" post="is associated with decreased mortality in severe coronavirus disease"/>
  <result pre="J Med. (2020) 382:1677â€&quot;9. 10.1056/NEJMp200376232109012 30.HoehlSRabenauHBergerAKortenbuschMCinatlJBojkovaDet al.. Evidence of SARS-CoV-2" exact="infection" post="in returning travelers from Wuhan, China. N Engl J"/>
  <result pre="382:1278â€&quot;80. 10.1056/NEJMc200189932069388 31.JinYHCaiLChengZSChengHDengTFanYPet al.. A rapid advice guideline for the" exact="diagnosis" post="and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia"/>
  <result pre="31.JinYHCaiLChengZSChengHDengTFanYPet al.. A rapid advice guideline for the diagnosis and" exact="treatment" post="of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)."/>
  <result pre="(2020) 8:506â€&quot;17. 10.1016/S2213-2600(20)30161-232272080 34.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.. Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
  <result pre="Chin Med J. (2020) 133:1261â€&quot;7. 10.1097/CM9.000000000000082432209890 38.WangLLiXChenHYanSLiDLiYet al.Coronavirus disease 19" exact="infection" post="does not result in acute kidney injury: an analysis"/>
  <result pre="(2020). 10.1101/2020.03.04.20031120. [Epub ahead of print]. 57.VargaZFlammerAJSteigerPHabereckerMAndermattRZinkernagelASet al.. Endothelial cell" exact="infection" post="and endotheliitis in COVID-19. Lancet. (2020) 395:1417â€&quot;8. 10.1016/S0140-6736(20)30937-532325026 58.SuHYangMWanCYiLXTangFZhuHYet"/>
  <result pre="transplantation. N Engl J Med. (2020) 382:2475â€&quot;7. 10.1056/NEJMc201111732329975 67.BanerjeeDPopoolaJShahSSterICQuanVPhanishM. COVID-19" exact="infection" post="in kidney transplant recipients. Kidney Int. (2020) 97:1076â€&quot;82. 10.1016/j.kint.2020.03.01832354637"/>
  <result pre="(2020). 10.1101/2020.03.17.20037432. [Epub ahead of print]. 90.BeigelJHTomashekKMDoddLEMehtaAKZingmanBSKalilACet al.Remdesivir for the" exact="treatment" post="of Covid-19â€&quot;Preliminary report. N Engl J Med. (2020). 10.1056/NEJMoa2007764."/>
  <result pre="Infect. (2020). 10.1016/j.jinf.2020.03.044. [Epub ahead of print].32283154 96.XuXHanMLiTSunWWangDFuBet al.. Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumab. Proc Natl Acad"/>
  <result pre="series. medRxiv. (2020). 10.1101/2020.04.15.20067017. [Epub ahead of print]. 99.LianNXieHLinSHuangJZhaoJLinQ. Umifenovir" exact="treatment" post="is not associated with improved outcomes in patients with"/>
  <result pre="Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and ribavirin in the" exact="treatment" post="of patients admitted to hospital with COVID-19: an open-label,"/>
  <result pre="al.. Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmoset. J"/>
  <result pre="common marmoset. J Infect Dis. (2015) 212:1904â€&quot;13. 10.1093/infdis/jiv39226198719 111.LuH. Drug" exact="treatment" post="options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. (2020)"/>
  <result pre="print]. 114.MehraMRRuschitzkaFPatelANRetractionâ€&quot;Hydroxychloroquine or chloroquine with or without a macrolide for" exact="treatment" post="of COVID-19: a multinational registry analysis. Lancet. (2020). 10.1016/S0140-6736(20)31180-6."/>
  <result pre="Blood Purif. (2020) 49:255â€&quot;8. 10.1159/00050703932172242 120.StockmanLJBellamyRGarnerP. SARS: systematic review of" exact="treatment" post="effects. PLoS Med. (2006) 3:e343. 10.1371/journal.pmed.003034316968120 121.UccelliAde RosboNK. The"/>
  <result pre="Cardiovasc Pharmacol Ther. (2015) 20:36â€&quot;51. 10.1177/107424841453491624938456 123.YeQWangBMaoJ. The pathogenesis and" exact="treatment" post="of the â€˜Cytokine Storm' in COVID-19. J Infect. (2020)"/>
  <result pre="80:607â€&quot;13. 10.1016/j.jinf.2020.03.03732283152 124.ChenJHuCChenLTangLZhuYXuXet al.. Clinical study of mesenchymal stem cell" exact="treatment" post="for acute respiratory distress syndrome induced by epidemic Influenza"/>
 </snippets>
</snippetsTree>
